Tony Chen
Global Guide 2024
Eminent Practitioners : Intellectual Property (International Firms)
Email address
[email protected]Contact number
+86.21.2201.8079Share profile
Eminent Practitioners
About
Provided by Tony Chen
Career
Tony Chen helps life science companies protect their products under China’s nascent pharmaceutical patent linkage system, and assists them with procuring patents, negotiating license agreements, and enforcing intellectual property rights in Chinese courts. He advises life science venture capital investors on mitigating IP risks associated with investing in Chinese biotechnology companies. He also acts for Chinese biotechnology clients in licensing technology and creating IP assets on a worldwide basis. Tony is Chairman of the Bayhelix Group, a network of senior executives in the cross-border China life science industry. Tony promotes the enhancement of pharmaceutical IP protection in China in his position as an advisory member of the U.S.-China IP Cooperation Dialogue organized by the U.S. Chamber of Commerce and Renmin University of China.
Chambers Review
Global
Tony Chen is a highly respected practitioner with considerable experience representing major clients in protection, enforcement and litigation matters concerning their IP rights. His practice encompasses invalidation and infringement proceedings, in addition to licensing matters and trade secrets litigation.
Strengths
Provided by Chambers
"Tony brings extensive experience on IP matters in life sciences. Not only is he very knowledgeable, but he is also well connected in the industry and can bring practical insights to the discussion."
"Tony understands our perspective very well. He is knowledgeable about Chinese pharmaceutical companies and the new regulations in China."
"Tony brings extensive experience on IP matters in life sciences. Not only is he very knowledgeable, but he is also well connected in the industry and can bring practical insights to the discussion."
"Tony understands our perspective very well. He is knowledgeable about Chinese pharmaceutical companies and the new regulations in China."